Overview: FIP1L1-PDGFRA Rearrangement TestIntroduction: The FIP1L1-PDGFRA Rearrangement Test detects FIP1L1-PDGFRA gene rearrangement linked to blood cancers, causing fatigue or eosinophilia. Aligned with 2023 ASH guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected hematologic malignancies.
Other Names: FIP1L1-PDGFRA Assay, Eosinophilia Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: FIP1L1-PDGFRA testing began in the 2000s with eosinophilia and leukemia research. PCR-based assays emerged in the 2010s, improving accuracy for gene rearrangement detection.
Purpose: Diagnoses blood cancers, guides targeted therapy, and monitors FIP1L1-PDGFRA rearrangement in patients with fatigue or eosinophilia.
Test Parameters: 1. FIP1L1-PDGFRA Rearrangement
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report symptoms like fatigue or eosinophilia, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, eosinophilia, or history of blood cancers (e.g., hypereosinophilic syndrome). Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for targeted therapy or genetic counseling.
Procedural Considerations: Uses PCR to detect FIP1L1-PDGFRA gene rearrangement. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Rare rearrangements may require additional testing.
Clinical Significance: Positive rearrangement results confirm blood cancer, prompting targeted therapy (e.g., imatinib). Negative results may require further genetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, eosinophil count, or other gene rearrangement tests to confirm blood cancers.
Test Limitations: False negatives may occur with rare rearrangements. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Gotlib J, 2022.
